Active Biotech’s Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology

Sep 20, 2011 08:30 (CEST) 
Lund, Sweden, September 20, 2011 - the Journal of Clinical Oncology
(http://jco.ascopubs.org/content/early/recent)has published an article*
presenting results from a controlled clinical Phase II study in 201 evaluable
patients of Active Biotech's (NASDAQ OMX Nordic: ACTI) prostate cancer project
TASQ.

It was concluded in the study that TASQ significantly slowed disease progression
and improved Progression Free Survival (PFS) in patients with metastatic
castrate-resistant prostate cancer (CRPC), alongside an acceptable side effect
profile. Six month progression free proportion of patients for TASQ and placebo
treatment groups were 69% and 37%, respectively (p<0.0001), with a median PFS of
7.6 vs. 3.3 months (p=0.0042).

Enrollment  of patients  to a  pivotal Phase  III trial  was initiated  in March
2011. The  Phase  III  study  is  a  global,  randomized, double-blind, placebo-
controlled  study in patients with  metastatic CRPC. The aim  of the study is to
confirm  TASQ's  effect  on  the  disease,  with radiological PFS as the primary
endpoint  and overall  survival as  secondary endpoint.  The planned  study will
include about 1,200 patients in more than 250 clinics.




Active Biotech AB (publ)

Tomas Leanderson
President & CEO



For further information, please contact
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson@activebiotech.com



*Phase  II Randomized, Double-Blind, Placebo-Controlled  Study of Tasquinimod in
Men  With  Minimally  Symptomatic  Metastatic Castrate-Resistant Prostate Cancer
Pili,  R.,,  Häggman,  M.,  Stadler.  W.,  Gingrich, J., Assikis, V., Björk, A.,
Nordle, Ö., Forsberg, G., Carducci, M., Armstrong, A.



Notes to editors

About TASQ
The  development  of  TASQ  is  principally  focused on the treatment ofprostate
cancer.  TASQ is an antiangiogenic compound, meaning that it cuts off the supply
of  nutrients to the tumor. Studies have concluded that TASQ exhibits anti-tumor
activity  via  inhibition  of  tumor  angiogenesis.  The  up-regulation  of  the
anti­angiogenic  protein thrombospondin-1 (TSP1) is a part of this mechanism. It
was  announced  in  December  2009 that  the  primary  endpoint  of the Phase II
clinical  study,  to  show  a  higher  fraction  of  patients  with  no  disease
progression during the six-month period of treatment using TASQ, had been met.


Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally   administered  compounds,  57- 57 for  Systemic  Sclerosis  as  well  as
RhuDex(TM) for RA. Please visit www.activebiotech.com  for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00



Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on September 20, 2011.




Active Biotech’s Prostate Cancer Project TASQ Featured in JCO:
http://hugin.info/1002/R/1548081/475708pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1548081]